Truscreen Group (ASX:TRU) Tax Expense: A$0.00 Mil (TTM As of Mar. 2026)


What is Truscreen Group Tax Expense?

Truscreen Group ASX:TRU Tax Expense is A$0.00 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Truscreen Group's tax expense for the months ended in Mar. 2026 was A$0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.00 Mil.


Truscreen Group  (ASX:TRU) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Truscreen Group Tax Expense Related Terms


Truscreen Group Tax Expense Historical Data

* Premium members only.

The historical data trend for Truscreen Group's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Truscreen Group Tax Expense Chart

Truscreen Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Truscreen Group Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Mar26
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Truscreen Group Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of A$0.00 Mil mean?
Truscreen Group (ASX:TRU) has a Tax Expense of A$0.00 Mil as of Mar. 2026. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Truscreen Group and its competitors.
Is Truscreen Group's Tax Expense too high?
Truscreen Group's current Tax Expense is A$0.00 Mil.
How does Truscreen Group's Tax Expense compare to ABT and SYK?
Truscreen Group's Tax Expense of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Medical Devices & Instruments company?
A good Tax Expense depends on the Medical Devices & Instruments industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Truscreen Group and its competitors. Truscreen Group's current Tax Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 40% below its estimated fair value. The current Tax Expense is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current Tax Expense is A$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Truscreen Group Business Description

Other Exchanges TRU:New Zealand
Address C/- HLB Mann Judd Limited, 57 Symonds Street, Level 6, Equitable House, Grafton, Auckland, NZL, 1010
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.